Yu Tao, Li Xiaolu, Wang Chao, Yang Yanyan, Fu Xiuxiu, Li Tianxiang, Wang Wentao, Liu Xiangyu, Jiang Xiaoxin, Wei Ding, Wang Jian-Xun
Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao 266021, People's Republic of China.
Department of Cardiac Ultrasound, The Affiliated hospital of Qingdao University, Qingdao 266000, People's Republic of China.
Research (Wash D C). 2025 Aug 12;8:0799. doi: 10.34133/research.0799. eCollection 2025.
Aortic dissection (AD) is a cardiovascular disorder with a high mortality rate. Lysine Lactylation (Kla), a novel posttranslational modification, critically regulates inflammation, tumors, and cardiovascular diseases. However, its specific role in AD pathogenesis remains unexplored. Using modification omics, we conducted a macroscopic analysis of the occurrence of extensive lactylation modification in aortic dissection and identified extensive lactylation, particularly in the adenosine triphosphatase activity pathway. Among these proteins, adenosine triphosphate (ATP) synthase F1 subunit α (ATP5F1A), a subunit in the ATP synthase complex, exhibited pronounced lactylation at the K531, catalyzed by sirtuin 3 (Sirt3). Through site-directed mutagenesis (K531R/K531E), we validated the key mechanism of lactylation activation at the K531 site of ATP5F1A and the regulatory enzymes. Functionally, K531 lactylation impairs ATP synthase activity, elevates reactive oxygen species generation, reduces ATP generation, and induces mitochondrial structural abnormalities. These effects ultimately contribute to the phenotypic transformation of human aortic vascular smooth muscle cells and enhanced synthesis and secretion of matrix metalloproteinases. In addition, we assessed the potential therapeutic effect of lactylation inhibition in aortic dissection using a mouse model and a drug based in vivo lactate alteration strategy. In conclusion, targeting the lactate-Sirt3-ATP5F1A axis represents a promising therapeutic strategy for blocking the progression of aortic dissection.
主动脉夹层(AD)是一种死亡率很高的心血管疾病。赖氨酸乳酰化(Kla)是一种新型的翻译后修饰,对炎症、肿瘤和心血管疾病起着关键的调节作用。然而,其在AD发病机制中的具体作用仍未得到探索。我们利用修饰组学技术,对主动脉夹层中广泛发生的乳酰化修饰进行了宏观分析,并鉴定出广泛的乳酰化现象,尤其是在三磷酸腺苷酶活性途径中。在这些蛋白质中,三磷酸腺苷(ATP)合酶F1亚基α(ATP5F1A)是ATP合酶复合物中的一个亚基,在K531位点表现出明显的乳酰化,由沉默调节蛋白3(Sirt3)催化。通过定点诱变(K531R/K531E),我们验证了ATP5F1A的K531位点乳酰化激活的关键机制以及调节酶。在功能上,K531位点的乳酰化会损害ATP合酶的活性,增加活性氧的产生,减少ATP的生成,并诱导线粒体结构异常。这些作用最终导致人主动脉血管平滑肌细胞的表型转化,并增强基质金属蛋白酶的合成和分泌。此外,我们使用小鼠模型和基于体内乳酸改变策略的药物评估了乳酰化抑制在主动脉夹层中的潜在治疗效果。总之,靶向乳酸-Sirt3-ATP5F1A轴是一种很有前景的治疗策略,可阻断主动脉夹层的进展。